AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas

By /

On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.

Scroll to Top